Sorafenib has also been shown in preclinical tests to be effective in a variety of tumor cells, including breast cancer MDA-MB-231 (with G463V b-raf and k-ras gene mutations), melanoma LOX, and pancreatic BxPC3 cells, as well as colon cancer HCT116, DLD-1, and Colo-205 cells [67] and other tumor cell lines. Here, KRAS is linked to neoplasm.